Prevnar 13 For Adults Canada

Prevnar 13 For Adults Canada Average ratng: 7,3/10 8966reviews
Prevnar 13 For Adults Canada

Find a comprehensive guide to possible side effects including common and rare side effects when taking Pneumovax 23 (Pneumococcal Vaccine Polyvalent) for healthcare. Image credit: 123rf.com. Why do people get the flu after getting the flu shot? This article is in response to the several significant errors Dr. Curchoe includes in. Dear Savvy Senior, What can you tell me about the flu shots made for seniors? I got sick last winter after getting a standard flu shot, and am wand.

PCV Vaccine Exposed – Breeding Ground For Staphylococcus Aureus « Vaccine Resistance Movement. The road- map leading to most neurological & neuro- developmental disorders traces back to the earliest vaccines administered to babies (HEP B, DTa. P, PCV, RV, HIB, IPV, MMR). Timing is the key – a premature breach of the delicate, under- developed “electrical grid network” designed to protect the baby’s brain & nervous system (Myelin Sheath, Blood- Brain Barrier, Meninges). According to the CDC’s ‘Recommended Immunization Schedule for Persons Aged 0 Through 6 Years—United States • 2.

Hepatitis B, Rotavirus, HIB (Haemophilus Influenzae Type b), IPV (Inactivated Polio Vaccine) & Hepatitis A, 4 doses of DPT (Diphtheria, Pertussis, Tetanus) & PCV (Pneumococcal Conjugate Vaccine), 1 dose of Varicella & Meningococcal and 2 doses of MMR (Measles, Mumps, Rubella). Often overlooked as a major catalyst in vaccine related trauma (typically in deference to the Measles, Mumps, Rubella shots), it turns out the hidden dangers of the PCV Vaccine may, in fact, supersede those of the MMR series – for a number of critical reasons; a combination of factors, chiefly timing & the extreme nature of bacterial build- up impinging on the under- developed Immune system in babies. All vaccinated children in the Western hemisphere are now carriers of what is known as MRSA (Methicillin- resistant Staphylococcus aureus/anti- biotic resistant super- bug), due to cross- infection primarily from the routine administering of the Pneumococcal (PCV) Vaccine – in combination with post vaccination anti- biotic & anti- viral drug treatment, an accumulative assault which strips a child of his/her natural anti- biotic resistance whilst infecting them with a host of bacterial serotypes (1, 3, 4, 5, 6. A, 6. B, 7. F, 9. V, 1. 4, 1. 8C, 1.

  1. 36 Responses to “VRM: PCV Vaccine Exposed – Breeding Ground For Staphylococcus Aureus”.
  2. Background In early 2000, a protein–polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed in the United States for use in young children.

A, 1. 9F, 2. 3F) – …leaving them totally vulnerable to Middle ear infections, high- grade seizures, Pneumonia, Myocarditis (inflammation of the heart muscle), Endocarditis (inflammation of the inner lining of the heart valves), Osteomyelitis (acute or chronic inflammatory process of the bone), Toxic Shock Syndrome (TSS), Bacteremia (presence of viable bacteria in the circulating blood) & Septicemia (blood poisoning), Meningitis (inflammation of the membranes/meninges surrounding the brain & spinal cord, usually due to the spread of an infection), and even sudden death. The current generation have literally become unwitting hosts to a form of bacterial roulette, an ideal breeding ground for the proliferation & weaponizing of bacterial infections.

The PCV Vaccine PREVNAR (Pneumococcal 7- valent Conjugate Vaccine: Diphtheria CRM1. Protein – manufactured by Pfizer/Wyeth), introduced in 2. West, and its later version PCV1. Pneumococcal 1. 3- valent Conjugate Vaccine [Diphtheria CRM1. Protein]), approved by the FDA on February 2. HIV/AIDS, cancer, damaged/absent spleen). According to the CDC it is ostensibly designed to project against “blood infections, pneumonia, and meningitis, mostly in young children…deafness and brain damage.”Hospitals around the world have concurrently reported a dramatic spike in the incidence & virulence of Methicillin- Resistant Staphylococcus aureus since 2.

In the United States in particular, ‘Since 2. MRSA infections in previously unaffected outpatient populations…a dramatic shift in the microbial flora of soft tissue infections has occurred recently in the United States.

Popovich et al. in 2. Chicago’s Stroger Hospital/Rush University Medical Center that showed a stable rate of hospital acquired strains of MRSA infections, but a rapidly increasing rate of community acquired strains of MRSA seen in the hospital from 2.

January 2. 00. 0 and June 2. July 2. 00. 3 and December 2. Note: This increase coincides precisely with the release of the first.

Pneumococcal (PCV) Vaccine on the market – ‘PCV7, containing the 7 most common pneumococcal serotypes causing invasive infections in children in North America was licensed in the US and recommended for routine use in infants in 2. Elsewhere the same trend is being documented.

In Queensland, Eastern Australia, in 2. MRSA strains causing infections among inpatients demonstrated an increase from 7. MDR (i. e., resistant to at least one non- β- lactam antibiotic and susceptible to ciprofloxacin)- resistant strains. A similar large increase was documented among outpatients during this period, from 5.

MDR MRSA strains.’‘The main antimicrobial resistance profiles changed from TC- GM- CI- EM- CM in 2. TC- GM- CIEM- CM- RI in 2.

The main pulsed- field gel electrophoresis type changed from types C, L, and E in 2. J, F, and N, respectively, in 2. ST2. 39- MRSA- III was the most predominant clone in 2. ST5- MRSA- II was found only in 2. Conclusions: There were increasing levels of antimicrobial resistance and epidemiological changes in the hospital- associated MRSA strains isolated in this facility between 2.

Amoxicillin Monograph for Professionals - Drugs. Class: Aminopenicillins. Chemical Name: [2. S- [2α,5α,6β(S*)]]- 6- [[Amino(4- hydroxyphenyl)acetyl]amino]- 3,3- dimethyl- 7- oxo- 4- thia- 1- azabicyclo[3. CAS Number: 6. 13. Brands: Amoxil, Trimox, Prevpac. Treatment of acute otitis media (AOM).

AAP, AAFP, CDC, and others recommend amoxicillin as drug of first choice for initial treatment of AOM,1. C)2. 44 or the infection is suspected of being caused by β- lactamase- producing Haemophilus influenzae or Moraxella catarrhalis, in which case the fixed combination of amoxicillin and clavulanate is recommended for initial treatment. Those who fail to respond to amoxicillin should be retreated with amoxicillin and clavulanate. Has been used for prevention of recurrent AOM†. Such prophylaxis not generally recommended.

Use only in selected patients with > 3 episodes within 6 months or > 4 episodes within 1. Has been used for management of otitis media with effusion† (OME). Anti- infectives not usually recommended; 1. AAP, AAFP, and others recommend watchful waiting for 3 months from date of effusion onset or diagnosis in those 2 months to 1. If anti- infectives are used, amoxicillin or the fixed combination of amoxicillin and clavulanate recommended. Treatment of pharyngitis and tonsillitis caused by Streptococcus pyogenes (group A β- hemolytic streptococci). AAP, IDSA, AHA, and others recommend oral penicillin V or IM penicillin G benzathine as treatments of choice; 1.

Amoxicillin sometimes used instead of penicillin V, especially for young children. A second episode can be retreated with the same or other treatment of choice; 1. G benzathine with or without rifampin) recommended for symptomatic patients with multiple, recurrent episodes.

Consider that multiple, recurrent episodes of symptomatic pharyngitis within several months to years may indicate a streptococcal carrier experiencing repeated episodes of nonstreptococcal (e. Treatment of lower respiratory tract infections caused by susceptible Streptococcus (α- or β- hemolytic strains only), S. Staphylococcus, or H. Treatment of skin and skin structure infections caused by susceptible Streptococcus (α- or β- hemolytic strains only), Staphylococcus, or Escherichia coli. Treatment of UTIs caused by susceptible Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. A drug of choice for treatment of uncomplicated UTIs caused by E.

E. coli and other Enterobacteriaceae. Previously used for treatment of acute uncomplicated gonorrhea (anogenital and urethral) caused by susceptible Neisseria gonorrhoeae. No longer recommended for gonorrhea by CDC or other experts. Alternative for treatment of typhoid fever† (enteric fever) caused by susceptible Salmonella typhi. Best Place To Vacation In The Caribbean For Young Adults.

Drugs of choice are fluoroquinolones and third generation cephalosporins (e. S. typhi (strains resistant to ampicillin, amoxicillin, chloramphenicol, and/or co- trimoxazole) reported with increasing frequency. Treatment of chronic carriers of S. Alternative for treatment of gastroenteritis caused by nontyphoidal Salmonella†. Anti- infectives not indicated in otherwise healthy individuals with uncomplicated (noninvasive) gastroenteritis, but recommended if gastroenteritis is severe and in those at increased risk of invasive disease (e. GI disease, severe colitis; immunocompromised because of malignancy, immunosuppressive therapy, HIV infection). Drugs of choice are fluoroquinolones, third generation cephalosporins (cefotaxime, ceftriaxone), ampicillin, amoxicillin, co- trimoxazole, or chloramphenicol, depending on in vitro susceptibility.

Treatment of Helicobacter pylori infection and duodenal ulcer disease (active or 1- year history of duodenal ulcer); 1. H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Used in a multidrug regimen that includes amoxicillin, clarithromycin, and either lansoprazole or omeprazole (triple therapy). Used with lansoprazole (dual therapy) in those allergic to or intolerant of clarithromycin or when clarithromycin resistance is suspected. Treatment of early localized or early disseminated Lyme disease† associated with erythema migrans, in the absence of neurologic involvement or third- degree AV heart block. IDSA, AAP, and others consider amoxicillin a drug of choice for treatment of early localized or early disseminated Lyme disease when oral therapy is appropriate. May be used in those with mild Lyme carditis,9.

Lyme arthritis (without associated neurologic disease),9. Amoxicillin is the preferred oral agent for treatment in pregnant women and children < 8 years of age who should not receive doxycycline.

Treatment of uncomplicated urethritis and cervicitis caused by Chlamydia trachomatis in pregnant women†. CDC and others recommend amoxicillin or a macrolide (azithromycin, erythromycin) as drugs of choice for treatment of urogenital chlamydial infections in these women.

Flu Shots for Seniors Huff. Post. Dear Savvy Senior,What can you tell me about the flu shots made for seniors? I got sick last winter after getting a standard flu shot, and am wandering if the flu vaccine for older adults would provide me better protection this year.—Almost 7. Dear Almost,There are actually two different flu shots – the Fluzone High Dose and FLUAD – that are designed specifically for people age 6. These FDA approved vaccines are designed to offer extra protection beyond what a standard flu shot provides, which is important for older adults who have weaker immune defenses and have a great risk of developing dangerous flu complications.

The Center for Disease Control and Prevention (CDC) estimates that the flu puts more than 2. You also need to be aware that these senior- specific flu shots cannot guarantee that you won’t get the flu this season, but they will lower your risk. And if you do happen to get sick, you probably won’t get as sick as you would without it. Here’s more information on the two vaccines: Fluzone High- Dose: Approved for U. S. use in 2. 00. 9, the Fluzone High- Dose is a high- potency vaccine that contains four times the amount of antigen as a regular flu shot does, which creates a stronger immune response for better protection.

This vaccine, according to a 2. FLUAD: Available in the U.

S. since last year, the FLUAD vaccine contains an added ingredient called adjuvant MF5. In a 2. 01. 2 Canadian observational study, FLUAD was 6. The CDC, however, does not recommend one vaccination over the other, and to date, there have been no studies comparing the two vaccines. You should also know that both the Fluzone High- Dose and FLUAD can cause more of the mild side effects that can occur with a standard- dose flu shot, like pain or tenderness where you got the shot, muscle aches, headache or fatigue. And neither vaccine is recommended for seniors who are allergic to chicken eggs, or those who have had a severe reaction to a flu vaccine in the past. Both vaccines are also covered 1.

Medicare Part B, as long as your doctor, health clinic or pharmacy agrees not to charge you more than Medicare pays. Pneumonia Vaccines.

Two other important vaccinations the CDC recommends to seniors, especially this time of year, are the pneumococcal vaccines for pneumonia. Around 1 million Americans are hospitalized with pneumonia each year, and about 5. The CDC is now recommending that all seniors, 6. Prevnar 1. 3 and Pneumovax 2. Both vaccines, which are administered just once at different times, work in different ways to provide maximum protection.

If you haven’t yet received any pneumococcal vaccine you should get the Prevnar 1. Pneumovax 2. 3 six to 1. But if you’ve already been vaccinated with Pneumovax 2. Prevnar 1. 3. Medicare Part B covers both shots, if they are taken at least one year apart. To locate a vaccination site that offers any of these shots, visit Vaccines. ZIP code. Send your senior questions to: Savvy Senior, P.

O. Box 5. 44. 3, Norman, OK 7. Savvy. Senior. org.

Jim Miller is a contributor to the NBC Today show and author of “The Savvy Senior” book.

Pfizer Reports Second- Quarter 2. Results. NEW YORK- -(BUSINESS WIRE)- -Pfizer Inc. PFE) reported financial results for second- quarter 2. Adjusted diluted EPS(2) and reaffirmed its 2.

Revenues. Results for the second quarter and first six months of 2. OVERALL RESULTS   ($ in millions, except per share amounts)   Second- Quarter     Six Months 2. Change 2. 01. 7   2. Change Revenues $   1. Reported Net Income(1) 3,0.

Reported Diluted EPS(1) 0. Adjusted Income(2) 4,0. Adjusted Diluted EPS(2) 0.

REVENUES   ($ in millions) Second- Quarter     Six Months   2. Change   2. 01. 7     2. Change     Total   Oper. Total   Oper. Innovative Health $ 7,6. Essential Health   5,2.

Total Company$1. 2,8. Excluding HIS revenues from all periods: Total Company$1. Essential Health 5,2. Acquisitions and divestitures completed in 2. Some amounts in this press release may not add due to rounding. All percentages have been calculated using unrounded amounts. References to operational variances pertain to period- over- period growth rates that exclude the impact of foreign exchange.(5)2.

FINANCIAL GUIDANCE(6)The midpoint of the guidance range for Adjusted diluted EPS(2) was increased by $0. Adjusted Other (Income)/Deductions(2) due to lower- than- forecasted net interest expense as well as higher- than- forecasted royalty income from certain products and dividend income from Vii. V Healthcare Ltd.

Vii. V). Additionally, the updated financial guidance absorbs $7. Adjusted research and development expenses(2) that were recorded in second- quarter 2. May 2. 01. 7 agreement with Sangamo Therapeutics, Inc. Sangamo) to develop and commercialize gene therapy programs for Hemophilia A. Pfizer’s updated 2. Revenues     $5. 2.

Adjusted Cost of Sales(2) as a Percentage of Revenues     2. Adjusted SI& A Expenses(2)     $1.

Adjusted R& D Expenses(2)     $7. Adjusted Other (Income)/Deductions(2)     Approximately $2.

Effective Tax Rate on Adjusted Income(2)     Approximately 2. Adjusted Diluted EPS(2) $2.

CAPITAL ALLOCATION During the first six months of 2. Pfizer returned $8. February 2. 01. 7 and completed in May 2.

Pfizer’s outstanding common stock. As of August 1, 2. Pfizer’s remaining share repurchase authorization was approximately $6. EXECUTIVE COMMENTARYIan Read, Chairman and Chief Executive Officer, stated, “I am pleased with our second- quarter 2. Revenues for the quarter increased 2% operationally, excluding the unfavorable impacts of the HIS divestiture and foreign exchange.

Innovative Health revenues grew 9% operationally, driven by the performance of our key growth drivers, notably Ibrance, Eliquis, Xeljanz and Xtandi. While Essential Health revenues for the quarter declined 1. I believe the continued strength from both businesses’ key growth drivers positions the Company for long- term success.“We have a strong pipeline with a steady flow of scientific innovation coming from all of our key therapeutic areas. Over the next five years, we project the potential for approximately 2. Our strategy remains focused on maximizing in- market opportunities while continuing to advance the pipeline and managing our cost structure to deliver attractive financial performance over time,” Mr. Read concluded. Frank D’Amelio, Executive Vice President, Business Operations and Chief Financial Officer, stated, “Today we raised the midpoint of our Adjusted diluted EPS(2) guidance range by $0.

Adjusted Other (Income)/Deductions(2) as well as our strong operational performance to date and confidence in the business going forward. The midpoint of our new guidance range for Adjusted diluted EPS(2) represents 7% growth compared with last year.”QUARTERLY FINANCIAL HIGHLIGHTS (Second- Quarter 2.

Second- Quarter 2. Second- quarter 2. Excluding the revenues for HIS in both periods and the unfavorable impact of foreign exchange, second- quarter 2. Second- quarter 2. Innovative Health Highlights IH revenues increased 9% operationally in second- quarter 2. Ibrance and Eliquis globally, the addition of Xtandi revenues in the U. S. resulting from the September 2.

Medivation, as well as Xeljanz and Lyrica, both primarily in the U. S. Global Ibrance revenues increased 6. Eliquis and Xeljanz was 5. Second- quarter 2. Enbrel in most developed Europe markets, primarily due to continued biosimilar competition. Global Prevnar 1. Prevenar 1. 3 revenues declined 7% operationally in second- quarter 2.

In the U. S., Prevnar 1. Adult indication due to a smaller remaining “catch up” opportunity compared to the prior- year quarter.

Prevenar 1. 3 revenues in international markets increased 8% operationally, primarily due to the favorable timing of government purchases in certain emerging markets for the pediatric indication. Essential Health Highlights Second- quarter 2.

EH revenues declined 1. February 2. 01. 7 divestiture of HIS. Second- quarter 2.

EH revenues were also negatively impacted by a 2. Peri- LOE Products, including declines in Pristiq in the U.

S., which lost marketing exclusivity in the U. S. in March 2. 01.